FDA Approves ' Rapid-Acting ' Oral Drug for Major Depression FDA Approves ' Rapid-Acting ' Oral Drug for Major Depression
The US Food and Drug Administration has approved dextromethorphan-bupropion (Auvelity), the first for an NMDA receptor antagonist for the treatment of major depressive disorder in adults.FDA Approvals
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Psychiatry News Alert Source Type: news
More News: Bupropion | Depression | Food and Drug Administration (FDA) | Internal Medicine | Psychiatry | Wellbutrin